BioTuesdays

Category - Markets

Wave Life Sciences
Markets

Mizuho starts Wave Life Sciences at buy

Mizuho Securities initiated coverage of Wave Life Sciences (NASDAQ:WVE) with a “buy” rating and price target of $34. The stock closed at $17.50 on August 16. Analyst Salim Syed writes that Wave is an idea-rich, nucleic...

August 18, 2017
Markets

HCW starts Alphatec at buy

H.C. Wainwright initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $4 price target, calling the company a “turnaround story in a high growth market.” The stock closed at $1.68 on August 11...

August 14, 2017
Novavax Logo
Markets

Ladenburg up Novavax to buy

Ladenburg Thalmann upgraded Novavax (NASDAQ:NVAX) to “buy” from “neutral” with a new price target of $1.60 after the company presented encouraging preclinical data from its nanoparticle influenza vaccine, NanoFlu, and...

August 9, 2017
AIT Therapeutics
Markets

Ladenburg starts AIT Therapeutics at buy

Ladenburg Thalmann launched coverage of AIT Therapeutics (NASDAQ:AITB) with a “buy” rating and $17 price target. The stock closed at $5.50 on Aug. 4. AIT is currently developing its proprietary nitric oxide (NOx) to...

August 7, 2017
Molecular Templates
Markets

Ladenburg starts Molecular Templates at buy

Ladenburg Thalmann initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $10.00 price target. The stock closed at $5.50 on August 2. “We believe the company’s Engineered Toxin Bodies (ETBs)...

August 3, 2017
STAAR Surgical
Markets

Canaccord ups STAAR price target to $11

Canaccord Genuity raised its price target for STAAR Surgical (NASDAQ:STAA) to $11 from $9 following the company’s second quarter results. The stock closed at $10.55 on August 2. Analyst Jason Mills, who said he was...

August 3, 2017
Apollo Endosurgery
Markets

Roth starts Apollo at buy

Roth Capital Partners initiated coverage of Apollo Endosurgery (NASDAQ:APEN) with a “buy” rating and target price of $10. The stock closed at $6.21 on August 2. “We believe Apollo is an attractive ‘masked growth’ Med...

August 3, 2017
IRadimed
Markets

Roth ups iRadimed to buy

Roth Capital Partners upgraded iRadimed (NASDAQ:IRMD) to “buy” from “neutral” and raised its price target to $12 from $9 after the company reported second quarter results. The stock closed at $9.80 on July 31. iRadimed...

August 1, 2017
AxoGen
Markets

Leerink starts Axogen at OP

Leerink launched coverage of Axogen (NASDAQ:AXGN) with an “outperform” rating and $22 price target. The stock closed at $15.10 on July 28. “We see Axogen as a unique and sustainable high-growth company, with a unique...

July 31, 2017
Intellipharmaceutics
Markets

Mackie cuts Intellipharmaceutics to sell

Mackie Research Capital downgraded Intellipharmaceutics International (NASDAQ, TSX:IPCI) to “sell” from “speculative buy” and slashed its price target to $1 from $6 after a FDA advisory committee voted 22-1 against...

July 28, 2017